Modulation of sAPP, sAPP alpha and BDNF levels in patients diagnosed with FXS and ASD

摘要

Autism spectrum disorder or fragile X syndrome comprising measuring BDNF, sAPP, and sAPP alpha plasma biomarker levels and adjusting the amount of therapeutic compound in response to the plasma levels of BDNF, sAPP, and sAPPα For the treatment and monitoring of patients diagnosed with In one embodiment, the therapeutic compound is acamprosate.